Article
Considerations on clinical trials of leprosy treatment: need of novel drug combinations
Registro en:
ILLARRAMENDI ROJAS, Ximena et al. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clin. Invest., v.3, n.7, p.617-635, 2013.
10.4155/CLI.13.52
Autor
Illarramendi Rojas, Ximena
Oliveira, Maria Leide Wand del Rey de
Sales, Ana Maria
Nery, José Augusto da Costa
Sarno, Euzenir Nunes
Resumen
Considering that after 30 years of using multidrug therapy (MDT), leprosy
eradication has still not been achieved, leprosy treatment must remain on
the drug discovery agenda. Due to the complexities inherent in leprosy
disease and the many methodological issues involved in clinical trials,
the task of translating the bench findings into clinical practice has been
arduous. While the effectiveness of reducing the currently recommended
MDT remains controversial, a number of highly bactericidal antibiotics
and immune-modulatory drugs have emerged as prospective candidates
to improve patient adherence and quality of life, reduce adverse effects
and prevent resistance. To replace the standard WHO-MDT, the new
combination must be the shortest, simplest and, consequently, most
affordable treatment possible.